← Ticker index
AMGN
Ticker
AMGN
Amgen Inc.
Healthcare
Congressional Trades
120
by 19 members
Ticker disclosure brief
Congressional disclosure records for AMGN
A ticker-first view of recent disclosures, reported ranges, filing lags, party aggregates, federal awards, lobbying records, and source-linked receipts.
Latest receipt
Ro Khanna
BUY · 2026-06-30
Largest range
$50K – $100K
C. Franklin
Longest observed gap
330d
C. Franklin
Highest 30d vs SPY
19.8%
Lisa McClain
Purchase rows
59
49%
Sale rows
56
47%
Disclosed midpoint
$2.0M
range estimate
Unique Traders
19
members
Disclosure timing method
Observed filing gaps are not notice-date findings
The reporting deadline is the earlier of 30 days after notice or 45 days after the transaction. Public disclosure rows provide transaction and filing dates, but do not establish when a member received notice. PoliWealth therefore marks only transaction-to-filing gaps over 45 days as an apparent delay for review; 31–45 day gaps are not labeled late from transaction date alone.
Party Breakdown
Democrats49 · 41%
Republicans71 · 59%
Lobbying filings
all →- 2026-07-10$38KAMGEN INC.Issues related to the pharmaceutical industry.
- 2026-06-12$5KAMGEN INC.Monitor healthcare regulations and statutes and educate members of Congress on issues with regard to client's interests
- 2026-06-12$0AMGEN INC.Educating members on issues affecting Amgen and patients
- 2026-06-02$0AMGEN INC.Issues related to the implementation of the Medicare Drug Negotiations and the calculation of the Medicaid Rebate and Best Price. issues relating to MFN pricing and other price controls in drugs.
- 2026-06-01$0AMGEN INC.Issues related to drug pricing and reimbursement for prescription drugs.
- 2026-04-22$10KAMGEN INC.Monitor healthcare regulations and statutes and educate members of Congress on issues with regard to client's interests
- 2026-04-20$2.6MAMGEN INCIssues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Ac
- 2026-04-20$80KAMGEN INC.Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022. Prescription Drug Pricing Policy. Supply Chain Issues. Prescription drug pricing policy.
- 2026-04-20$60KAMGEN INC.Healthcare policy issues as they relate to the pharmaceutical industry including drug pricing and biosimilars Issues related to drug pricing, biosimilars, Medicare Part D and Medicare Part B; H.R. 3517 - Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021 Issues related to visas
- 2026-04-20$60KAMGEN INC.General education about federal policies impacting pharmaceutical development, approval, and patient access. 340B, Policies impacting public health preparedness and prevention. Policies impacting Cardiovascular and bone health. Pharmacy benefit manager reform proposals. FDA reform, prescription drug reimportation and new proposals. Medicare Part D and Medicare Part B drug reimbursement, policies around MFN drug pricing, Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act" implementation, coverage and access for biosimilars. Tax issues related to the pharmaceutical industry. Implementation of PL 119-21. Policies impacting disease prevention. Issues related to antitrust legislation. Issues related to patent protections.
Loading trade analytics…
All Disclosed Trades
Page 2 · 25 of 120 shown| Date | Member | Action | Amount | Observed Gap | Receipt |
|---|---|---|---|---|---|
| 2026-01-23 | DRo Khanna | SELL | $15K – $50K | 14d | receipt → |
| 2026-01-23 | DRo Khanna | SELL | $15K – $50K | 14d | receipt → |
| 2026-01-16 | RDavid Taylor | BUY | $1K – $15K | 18d | receipt → |
| 2026-01-29 | RDavid Taylor | SELL | $1K – $15K | 5d | receipt → |
| 2026-01-16 | RDavid Taylor | BUY | $1K – $15K | 17d | receipt → |
| 2026-01-29 | RDavid Taylor | SELL | $1K – $15K | 4d | receipt → |
| 2024-10-23 | RJulia Letlow | BUY | $1K – $15K | 447dApparent delay | receipt → |
| 2024-10-23 | RJulia Letlow | BUY | $1K – $15K | 447dApparent delay | receipt → |
| 2024-11-19 | RJulia Letlow | SELL | $1K – $15K | 420dApparent delay | receipt → |
| 2024-11-19 | RJulia Letlow | SELL | $1K – $15K | 420dApparent delay | receipt → |
| 2025-12-03 | RDavid Taylor | SELL | $1K – $15K | 5d | receipt → |
| 2025-12-03 | RDavid Taylor | SELL | $1K – $15K | 2d | receipt → |
| 2025-12-03 | RDavid Taylor | SELL | $1K – $15K | 2d | receipt → |
| 2025-09-25 | RLisa McClain | SELL | $1K – $15K | 28d | receipt → |
| 2025-09-25 | RLisa McClain | SELL | $1K – $15K | 28d | receipt → |
| 2025-09-25 | RLisa McClain | SELL | $1K – $15K | 27d | receipt → |
| 2025-09-25 | RLisa McClain | SELL | $1K – $15K | 27d | receipt → |
| 2025-09-04 | DSheldon Whitehouse | SELL | $1K – $15K | 29d | receipt → |
| 2025-09-29 | DRo Khanna | SELL | $1K – $15K | 4d | receipt → |
| 2025-09-29 | DRo Khanna | SELL | $1K – $15K | 4d | receipt → |
| 2025-09-04 | DSheldon Whitehouse | SELL | $1K – $15K | 29d | receipt → |
| 2025-02-11 | RDaniel Meuser | SELL | $1K – $15K | 190dApparent delay | receipt → |
| 2025-02-11 | RDaniel Meuser | SELL | $1K – $15K | 190dApparent delay | receipt → |
| 2025-06-24 | RLisa McClain | BUY | $1K – $15K | 51dApparent delay | receipt → |
| 2025-06-24 | RLisa McClain | BUY | $1K – $15K | 50dApparent delay | receipt → |
“Observed gap” is the calendar distance from transaction date to filing date; only gaps over 45 days receive an apparent-delay marker.